Company: TAK
Filing Date: 2025-06-26
Form Type: 424B5
Source: 0001395064-25-000101
Chunk: 8

Company: TAKEDA PHARMACEUTICAL CO LTD
Filing Date: 2025-06-26
Form: 424B5
Chunk 8
---
 we have a very significant presence in the United States, Japan, and Europe as well as a fast-growing business in China. We have also accelerated our focus on data, digital and technology to make our business operations more effective and efficient, increase innovation and better serve our stakeholders.

See “Item 4.B. Information on the Company—Business Overview” in our annual report for the fiscal year ended March 31, 2025 on Form 20-F, which is incorporated herein by reference.

The address of TPC’s registered head office is 1-1 Nihonbashi Honcho 2-chome, Chuo-ku, Tokyo 103-8668, Japan. TPC’s telephone number is +81-3-3278-2306, and Takeda’s internet site is http://www.takeda.com. The information on Takeda’s internet site is not incorporated by reference herein and does not form a part of this prospectus supplement.

#### TAKEDA U.S. FINANCING, INC.
TUSFI is a Delaware corporation and the issuer of the Notes. It is TPC’s indirect wholly-owned finance subsidiary and issues debt securities for the benefit of Takeda.

The expectations described above are forward-looking statements based on Takeda’s assumptions and beliefs as of the date of this prospectus supplement and are subject to the qualifications set forth under “Cautionary Statement Regarding Forward-Looking Statements.” Takeda’s actual results may vary due to factors such as those discussed under “Item 3. Key Information—D. Risk Factors” of Takeda’s most recent annual report on Form 20-F filed with the SEC and in the “Risk Factors” section beginning on page S- 7 of this prospectus supplement or unanticipated events and circumstances.

<div align='center'>S-1</div>

### SUMMARY RISK FACTORS
Investing in the Notes involves a number of risks, and prospective investors are urged to carefully consider the matters discussed under “Risk Factors” prior to making an investment in the Notes. Such risks include, but are not limited to:

• Risks relating to the development, production and marketing of pharmaceutical products, such as:

◦ The expensive nature and uncertainty of research and development of pharmaceutical products;

◦ Government regulations over product development, regulatory approvals and reimbursement requirements;

◦ Laws and regulations governing the sales and marketing of our products;

◦ Government policies and other pressures to reduce medical costs;

◦ The expiration or loss